Year: 2022

To view notification click here

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company, is pleased to announce that the Company has agreed with Incanthera plc (“Incanthera”) that Warrants issued to the Company on 26 February 2020, in conjunction with Incanthera’s IPO onto the Aquis Exchange, are extended by a further period to 31 March 2025. Key highlights:…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2024 (the “Period”). Key Highlights (including post Period review) Financials Loss for the Period of £0.4m (30 June 2023: £0.8m) Research and development expenses of £0.5m (30…

TR-1: Standard form for notification of major holdings click here

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. The Company is pleased to announce that all resolutions were duly passed, details of which are contained in the table below. Resolution For % For Against % Against Withheld 1. To receive the accounts of the Company for the year…

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to confirm that the Company’s Annual General Meeting (“AGM”) will be held on Friday 28 June 2024 @ 11:00a.m. (BST), at the offices of Evelyn Partners, 45 Gresham Street, London, EC2V 7BG. The Notice of AGM setting out details of the…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its Final Results for the twelve months ended 31 December 2023 (the “Period”). Key Highlights (including post Period review) Financials Loss for the Period of £2.9m (2022:  £3.8m) Research and development expenses of £2.0m (2022: £2.0m) Administrative expenses of £1.0m (2022: £0.8m)…

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, announces that it has realised gross proceeds of c£1.5 million on the sale of its entire holding of c9.9 million shares in Incanthera plc. Following this transaction, ImmuPharma retains c7.3 million warrants in Incanthera plc which have an exercise price of 9.5p and…

To download details click here

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that Tim McCarthy, CEO and Dr Tim Franklin, COO, will be attending BIO-Equity. The event will be held from 12-14 May 2024, in San Sebastian, Spain. BIO-Equity is an annual premier partnering event, designed to provide biotechnology companies with the opportunity to present to…